Accenture, patient analytics

Boston Scientific and Accenture Leverage Digital Health for Cardiovascular Patients

By MedTech Intelligence Staff
No Comments
Accenture, patient analytics

The collaboration has resulted in a solution that aims to improve patient outcomes and reduce costs.

Boston Scientific Corp. and Accenture have teamed up to offer a cloud-based digital health product that is designed to help hospitals improve patient outcomes, reduce overall length of stay and readmission rates, and lower costs related to treating chronic cardiovascular diseases. The data-driven solution is currently being used on patients with heart failure, as the disease is one of the costliest to manage and generally results in longer hospital stays.

“We identified a 25% unnecessary heart failure readmissions rate, and therefore a definite need for better care coordination, supported by modern technology and processes that can decrease overall costs,” said Dr. Kari Niemelä, chief executive officer of Tampere Heart Hospital, in a press release. Located in Finland, Tampere Heart Hospital is one of two hospitals that Boston Scientific and Accenture worked with to assess the current state of care of heart failure patients, along with areas of improvement.

The Advantics Care Pathway Transformation solution focuses on pathway analytics (how a patient moves through the hospital system, including how long this takes), care management (how patients are diagnosed, treated and monitored), and patient engagement (how patients are educated, monitored and communicated with during and after their time in the hospital).

The companies plan to expand the digital health solution to other cardiovascular disease states in the future. The product will be made available to hospitals in the United Kingdom and Scandinavia, followed by pilot projects in Europe and the United States.

Related Articles

  • Bernstein_Mazur

    Rapid developments in healthcare technology, combined with improved data collection, pandemic pressures and increased consumer demand for tech-enabled and virtual health care, are fueling innovation and transformation in the digital health space.

  • Boston Scientific Logo

    “M.I.Tech is an innovator in nonvascular stent development, with product offerings that complement our existing stent portfolio.”

  • Leo Petrossian Head Shot

    The COVID-19 pandemic exposed the necessity of virtual care and revealed its possibility as a more efficient means of administering treatment in an overwhelmed and understaffed infrastructure. Its fast-paced adoption highlighted the need for global standards and third-party certifications.

  • Rogers-Headshot

    Digital therapeutics (DTx) have the potential to lower healthcare costs and improve patient compliance, outcomes and access to care. In the first part of this two-article series we look at the current and potential applications for this growing sector of…

Leave a Reply

Your email address will not be published. Required fields are marked *